Ansofaxine hydrochloride vs Liafensine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: Serotonin/norepinephrine/dopamine transporter · full Major Depressive Disorder pipeline

Ansofaxine hydrochloride

Marketed by Luye Pharma Group

Phase 3 in Major Depressive Disordersmall molecule
Reliable signal

NCT04853407 · Phase 3 · completed

This was a randomized, quadruple-blinded, placebo-controlled trial with 558 patients and a validated depression-severity scale as the primary endpoint. Both ansofaxine doses significantly outperformed placebo (MADRS reductions of 20.0 and 19.9 points versus 14.6 with placebo, p<0.0001).

Next expected readout: February 2027 · NCT06426485 (registry estimate)

Reported efficacy

Montgomery- Åsberg Depression Rating Scale(MADRS) (8 Weeks): MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001). (met)

Result source: NCT04853407

Liafensine

Developed by Denovo Biopharma and partners

Phase 2 in Major Depressive Disordersmall molecule
Reliable signal

NCT05113771 · Phase 2 · completed

The study randomized 197 participants to two liafensine doses or placebo, with participants and investigators blinded to treatment. Its primary clinical endpoint, change in MADRS score at Day 42 in DGM4-positive patients, favored combined liafensine over placebo with statistical significance, supporting a strong evidence grade.

Reported efficacy

Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31) (met)

Result source: NCT05113771

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnsofaxine hydrochlorideLiafensine
MADRS, change (acute)-19.9 vs -14.6a−5.3 vs placeboansofaxine 160 mg · wk 8NCT04853407
1 other result
  • -20 vs -14.6 ansofaxine 80 mg · wk 8 · Phase 3 · primary NCT04853407
-15.5 vs -11−4.5 vs placebo2mg · wk 6 · n 61NCT05113771
1 other result
  • -15.4 vs -11 1mg · wk 6 · n 62 · Phase 2 · primary NCT05113771
CGI-S, change (acute)—Not posted · NCT04853407-1.5 vs -1.1−0.4 vs placebo2mg · wk 6 · n 61NCT05113771
1 other result
  • -1.5 vs -1.1 1mg · wk 6 · n 62 · Phase 2 · secondary NCT05113771
MADRS response—Not posted · NCT04853407—Not reported
MADRS remission—Not posted · NCT04853407—Not reported
Relapse (% of patients)—Not posted · NCT04853407—Not reported

MADRS, change (acute)

Ansofaxine hydrochloride
-19.9 vs -14.6a−5.3 vs placeboansofaxine 160 mg · wk 8NCT04853407
1 other result
  • -20 vs -14.6 ansofaxine 80 mg · wk 8 · Phase 3 · primary NCT04853407
Liafensine
-15.5 vs -11−4.5 vs placebo2mg · wk 6 · n 61NCT05113771
1 other result
  • -15.4 vs -11 1mg · wk 6 · n 62 · Phase 2 · primary NCT05113771

CGI-S, change (acute)

Ansofaxine hydrochloride
—Not posted · NCT04853407
Liafensine
-1.5 vs -1.1−0.4 vs placebo2mg · wk 6 · n 61NCT05113771
1 other result
  • -1.5 vs -1.1 1mg · wk 6 · n 62 · Phase 2 · secondary NCT05113771

MADRS response

Ansofaxine hydrochloride
—Not posted · NCT04853407
Liafensine
—Not reported

MADRS remission

Ansofaxine hydrochloride
—Not posted · NCT04853407
Liafensine
—Not reported

Relapse (% of patients)

Ansofaxine hydrochloride
—Not posted · NCT04853407
Liafensine
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ansofaxine hydrochloride: 0 of 4 rows · Liafensine: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnsofaxine hydrochlorideLiafensine
Dropout rate—
24.6%2mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
6.2%1mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
Discontinued due to AEs—
—2mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
—1mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
Serious AEs—
4.7%2mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
0%1mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
Most frequent reported AEs—
2mg
headach 21.9% (placebo 22.4%)
constipation 9.4% (placebo 0%)
decreased appetite 9.4% (placebo 3%)
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
1mg
headach 30.8% (placebo 22.4%)
nausea 16.9% (placebo 10.4%)
dizziness 12.3% (placebo 7.5%)
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liafensine

CGI-S -1.5 vs -1.1 placebo score @ 6wk2mg
absolute change · score
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
-1.5 vs -1.1 placebo score @ 6wk1mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
CGI-I 2.4 vs 2.9 placebo score @ 6wk2mg
absolute value · score
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2
show 1 more result
2.3 vs 2.9 placebo score @ 6wk1mg
NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ansofaxine hydrochloride's landscape · Liafensine's landscape